SEC Comment Letter 0000000000-23-001195 to Can-Fite BioPharma Ltd. (CANF)
Can-Fite BioPharma Ltd.
Date: Feb. 6, 2023 · CIK: 0001536196 · Accession: 0000000000-23-001195
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-269485
Letter
United States securities and exchange commission logo February 6, 2023 Pnina Fishman, Ph.D. Chief Executive Officer Can-Fite BioPharma Ltd. 10 Bareket Street Kiryat Matalon P.O. Box 7537 Petach-Tikva 4951778, Israel Re:Can-Fite BioPharma Ltd. Registration Statement on Form F-1 Filed January 31, 2023 File No. 333-269485 Dear Pnina Fishman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Gary M. Emmanuel
Show Raw Text
United States securities and exchange commission logo
February 6, 2023
Pnina Fishman, Ph.D.
Chief Executive Officer
Can-Fite BioPharma Ltd.
10 Bareket Street
Kiryat Matalon
P.O. Box 7537
Petach-Tikva
4951778, Israel
Re:Can-Fite BioPharma Ltd.
Registration Statement on Form F-1
Filed January 31, 2023
File No. 333-269485
Dear Pnina Fishman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Gary M. Emmanuel